NCM · Biotechnology

Alzamend Neuro, Inc. (ALZN) Stock

$1.34 +0.00% NCM: ALZN Healthcare

Valuation

MetricValue
Price$1.34
Market Cap$5.10M
P/E Ratio-0.60
P/B Ratio1.06
P/S Ratio0.00
EPS (TTM)$-11.32
52-Week High$2.68
52-Week Low$0.84
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-277.88%
ROA-106.49%
ROCE-156.69%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-15.0M$-10.0M$-4.0M$-9.0M
Net Profit$-12.0M$-15.0M$-10.0M$-5.0M$-9.0M
EPS$-187.31$-205.97$-132.33$-11.32$-2.63
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$15.0M$6.0M$1.0M$5.0M$2.0M
Total Liabilities$1.0M$3.0M$3.0M$1.0M$1.0M
Cash$14.0M$5.0M$0$4.0M$1.0M
Borrowings$0$0$0$0$0

Latest News

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending PR Newswire · Aug 4, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-7.0M$-9.0M$-8.0M$-7.0M$-8.0M
Investing Cash Flow$0$0$0$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$12.0M$-9.0M$-5.0M$4.0M$-3.0M
Free Cash Flow$-7.0M$-9.0M$-8.0M$-7.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.26
FCF Yield-131.29%
Quick Ratio3.01
Interest Coverage818.59
Return 1Y-61.20%
Return 3Y-99.82%
Return 5Y-99.99%

Ownership

Insiders Held0.53%
Institutions Held3.04%
Institutions Float Held3.05%
Institutional HolderSharesReport Date
Geode Capital Management, LLC45,6802026-03-31
Vanguard Fiduciary Trust Co21,0202026-03-31
Morgan Stanley18,0002026-03-31
Clearstead Advisors, LLC10,0002026-03-31
Tower Research Capital LLC (TRC)6,1842026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is led by CEO Stephan Jackman, employs 4 people, headquartered in US, publicly traded since 2021.

Alzamend Neuro, Inc. (ALZN) stock trades at $1.34 with a market capitalization of $5.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.60, price-to-book of 1.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.84 and $2.68, and currently trades 50.0% below its 52-week high.

On profitability, Alzamend Neuro, Inc. generates a return on equity (ROE) of -277.88%, return on capital employed of -156.69%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides